Published in Medicine and Law Weekly, May 14th, 2004
"BMS-806 and the related compound, #155, are novel inhibitors of human immunodeficiency virus type 1 (HIV-1) entry that bind the gp120 exterior envelope glycoprotein," scientists in Boston explained. "BMS-806 and #155 block conformational changes in the HIV-1 envelope glycoproteins that are induced by binding to the host cell receptor, CD4.
In a recent study, N. Madani and colleagues at the Dana Farber Cancer Institute "tested a panel of HIV-1 envelope glycoprotein mutants and identified several that were resistant to the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine and Law Weekly